tiprankstipranks
Advertisement
Advertisement
Excellergy Advances First-in-Class Allergy Drug Exl-111 Into Phase 1, Backed by Strong Preclinical Data
PremiumPrivate CompaniesExcellergy Advances First-in-Class Allergy Drug Exl-111 Into Phase 1, Backed by Strong Preclinical Data
28d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100